ACLX
Arcellx Inc
Price Chart
Latest Quote
$115.07
+0.02 (+0.02%)
Current Price
| Previous Close | $115.05 |
| Open | $115.03 |
| Day High | $115.05 |
| Day Low | $115.05 |
| Volume | 13,191,486 |
Stock Information
| Shares Outstanding | 58.51M |
| Total Debt | $51.92M |
| Cash Equivalents | $450.33M |
| Revenue | $22.29M |
| Net Income | $-228.93M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.73B |
| EPS (TTM) | $-4.07 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.33B |
| Sales | $22.29M |
| Income | $-228.93M |
| Book/sh | $6.95 |
| Cash/sh | $7.70 |
| Employees | 209 |
Financial Ratios
| Quick Ratio | 4.32 |
| Current Ratio | 4.43 |
| Debt/Eq | 12.90 |
Returns & Margins
| ROA | -24.05% |
| ROE | -53.42% |
| Operating Margin | -3850.24% |
Ownership
| Insider Ownership | 11.67% |
| Institutional Ownership | 90.33% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -77.74 |
| P/S | 302.09 |
| P/B | 16.57 |
Analyst Data
| Recommendation | hold |
| Target Price | $112.20 |
Technical Indicators
| SMA20 | $114.93 |
| SMA50 | $111.71 |
| SMA200 | $83.94 |
| RSI | 74.55 |
| ATR | 0.0918 |
| Shares Float | 42.96M |
| Short Float | 4.18% |
| Short Ratio | 1.56 |
| Volatility | 0.25 |
Performance History
| Week | +0.06% |
| Month | +0.26% |
| Quarter | +68.87% |
| 6 Months | +32.72% |
| YTD | +81.67% |
| Year | +78.26% |
| 3 Years | +186.10% |
| 10 Years | +584.94% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-05-15 | $115.07 | 13,191,486 |
About Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. As of April 28, 2026, Arcellx, Inc. operates as a subsidiary of Gilead Sciences, Inc.
đ° Latest News
Gilead Sciences, Inc. (GILD) Outlook Cut Sharply on $11.5B IPR&D and Financing Costs
Insider Monkey âĸ 2026-05-11T20:01:13Z
Gilead Sciences Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-08T02:13:29Z
Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions
Reuters âĸ 2026-05-07T20:05:41Z
Hereâs Why Roivant Sciences Ltd (ROIV) Rallied in Q1
Insider Monkey âĸ 2026-05-04T13:10:00Z
Gileadâs HIV Priority Review And Arcellx Deal Refocus LongâTerm Story
Simply Wall St. âĸ 2026-05-02T10:09:59Z
Gilead Sciences Annual Meeting: Directors, Pay Win Big; Pipeline Launches and Acquisitions Highlighted
MarketBeat âĸ 2026-04-30T20:42:56Z
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Zacks âĸ 2026-04-27T13:40:02Z
Gilead Sciences (GILD) Set to Acquire Arcellx
Insider Monkey âĸ 2026-04-27T06:04:51Z
Gilead Deepens Oncology Reach And HIV Prevention With Arcellx And Lenacapavir
Simply Wall St. âĸ 2026-04-19T13:02:54Z
Gileadâs Tubulis Deal Recasts Oncology Ambitions And HIV Reliance Risks
Simply Wall St. âĸ 2026-04-11T00:24:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $22,286,000 | $107,936,000 | $110,319,000 | $0 |
| Operating Revenue | $22,286,000 | $107,936,000 | $110,319,000 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $1,030,000 | $3,842,000 | $1,720,000 |
| Total Expenses | $275,369,000 | $245,507,000 | $200,199,000 | $191,259,000 |
| Net Non Operating Interest Income Expense | $24,218,000 | $32,292,000 | $19,853,000 | $2,580,000 |
| Interest Expense Non Operating | $0 | $1,030,000 | $3,842,000 | $1,720,000 |
| Operating Expense | $275,369,000 | $245,507,000 | $200,199,000 | $191,259,000 |
| General And Administrative Expense | $117,758,000 | $88,414,000 | $66,350,000 | $41,704,000 |
| Other Income Expense | - | - | - | - |
| Other Non Operating Income Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-228,934,000 | $-107,348,000 | $-70,690,000 | $-188,679,000 |
| Net Interest Income | $24,218,000 | $32,292,000 | $19,853,000 | $2,580,000 |
| Interest Income | $24,218,000 | $33,322,000 | $23,695,000 | $4,300,000 |
| Normalized Income | $-228,934,000 | $-107,348,000 | $-70,690,000 | $-188,679,000 |
| Net Income From Continuing And Discontinued Operation | $-228,934,000 | $-107,348,000 | $-70,690,000 | $-188,679,000 |
| Total Operating Income As Reported | $-253,083,000 | $-137,571,000 | $-89,880,000 | $-191,259,000 |
| Net Income Common Stockholders | $-228,934,000 | $-107,348,000 | $-70,690,000 | $-188,679,000 |
| Net Income | $-228,934,000 | $-107,348,000 | $-70,690,000 | $-188,679,000 |
| Net Income Including Noncontrolling Interests | $-228,934,000 | $-107,348,000 | $-70,690,000 | $-188,679,000 |
| Net Income Continuous Operations | $-228,934,000 | $-107,348,000 | $-70,690,000 | $-188,679,000 |
| Pretax Income | $-228,865,000 | $-105,279,000 | $-70,027,000 | $-188,679,000 |
| Interest Income Non Operating | $24,218,000 | $33,322,000 | $23,695,000 | $4,300,000 |
| Operating Income | $-253,083,000 | $-137,571,000 | $-89,880,000 | $-191,259,000 |
| Per Share | ||||
| Diluted EPS | - | $-2.00 | $-1.47 | $-5.19 |
| Basic EPS | - | $-2.00 | $-1.47 | $-5.19 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-222,187,000 | $-99,061,000 | $-64,145,000 | $-185,638,000 |
| Reconciled Depreciation | $6,678,000 | $5,188,000 | $2,040,000 | $1,321,000 |
| EBITDA (Bullshit earnings) | $-222,187,000 | $-99,061,000 | $-64,145,000 | $-185,638,000 |
| EBIT | $-228,865,000 | $-104,249,000 | $-66,185,000 | $-186,959,000 |
| Diluted NI Availto Com Stockholders | $-228,934,000 | $-107,348,000 | $-70,690,000 | $-188,679,000 |
| Tax Provision | $69,000 | $2,069,000 | $663,000 | $0 |
| Research And Development | $157,611,000 | $157,093,000 | $133,849,000 | $149,555,000 |
| Selling General And Administration | $117,758,000 | $88,414,000 | $66,350,000 | $41,704,000 |
| Other Gand A | $117,758,000 | $88,414,000 | $66,350,000 | $41,704,000 |
| Diluted Average Shares | - | $53,566,153 | $48,061,450 | $36,355,758 |
| Basic Average Shares | - | $53,566,153 | $48,061,450 | $36,355,758 |
Fetched: 2026-04-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $402,351,000 | $454,792,000 | $485,380,000 | $204,954,000 |
| Total Assets | $603,990,000 | $711,327,000 | $825,132,000 | $313,817,000 |
| Total Non Current Assets | $141,807,000 | $112,017,000 | $108,769,000 | $46,954,000 |
| Other Non Current Assets | $5,624,000 | $3,495,000 | $11,774,000 | $7,064,000 |
| Investmentin Financial Assets | $69,716,000 | $38,277,000 | $27,168,000 | $0 |
| Current Assets | $462,183,000 | $599,310,000 | $716,363,000 | $266,863,000 |
| Other Current Assets | $7,823,000 | $5,845,000 | $5,679,000 | $3,667,000 |
| Restricted Cash | $0 | $208,000 | $1,903,000 | $0 |
| Prepaid Assets | $4,026,000 | $5,882,000 | $6,764,000 | $8,361,000 |
| Cash Cash Equivalents And Short Term Investments | $450,334,000 | $587,375,000 | $702,017,000 | $254,835,000 |
| Cash And Cash Equivalents | $80,262,000 | $105,679,000 | $394,583,000 | $64,179,000 |
| Non Current Deferred Assets | - | - | - | $0 |
| Debt | ||||
| Total Debt | $51,919,000 | $54,080,000 | $97,625,000 | $88,131,000 |
| Long Term Debt And Capital Lease Obligation | $44,339,000 | $46,542,000 | $50,841,000 | $52,170,000 |
| Current Debt And Capital Lease Obligation | $7,580,000 | $7,538,000 | $46,784,000 | $35,961,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $201,639,000 | $256,535,000 | $339,752,000 | $108,863,000 |
| Total Non Current Liabilities Net Minority Interest | $97,437,000 | $131,130,000 | $221,514,000 | $52,170,000 |
| Non Current Deferred Liabilities | $53,098,000 | $75,995,000 | $170,673,000 | $0 |
| Current Liabilities | $104,202,000 | $125,405,000 | $118,238,000 | $56,693,000 |
| Other Current Liabilities | $4,360,000 | $8,531,000 | $8,214,000 | $3,131,000 |
| Current Deferred Liabilities | $55,967,000 | $59,056,000 | $50,533,000 | $0 |
| Payables And Accrued Expenses | $21,733,000 | $39,842,000 | $7,178,000 | $12,254,000 |
| Payables | $11,134,000 | $23,335,000 | $2,619,000 | $9,053,000 |
| Accounts Payable | $5,576,000 | $2,095,000 | $2,619,000 | $9,053,000 |
| Other Non Current Liabilities | - | $8,593,000 | - | - |
| Equity | ||||
| Common Stock Equity | $402,351,000 | $454,792,000 | $485,380,000 | $204,954,000 |
| Total Equity Gross Minority Interest | $402,351,000 | $454,792,000 | $485,380,000 | $204,954,000 |
| Stockholders Equity | $402,351,000 | $454,792,000 | $485,380,000 | $204,954,000 |
| Gains Losses Not Affecting Retained Earnings | $843,000 | $848,000 | $547,000 | $-221,000 |
| Other Equity Adjustments | $843,000 | $848,000 | $547,000 | $-221,000 |
| Retained Earnings | $-725,762,000 | $-496,828,000 | $-389,480,000 | $-318,790,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $0 |
| Other | ||||
| Ordinary Shares Number | $57,929,325 | $54,293,597 | $52,280,077 | $44,105,981 |
| Share Issued | $57,929,325 | $54,293,597 | $52,280,077 | $44,105,981 |
| Tangible Book Value | $402,351,000 | $454,792,000 | $485,380,000 | $204,954,000 |
| Invested Capital | $402,351,000 | $454,792,000 | $485,380,000 | $204,954,000 |
| Working Capital | $357,981,000 | $473,905,000 | $598,125,000 | $210,170,000 |
| Capital Lease Obligations | $51,919,000 | $54,080,000 | $97,625,000 | $88,131,000 |
| Total Capitalization | $402,351,000 | $454,792,000 | $485,380,000 | $204,954,000 |
| Additional Paid In Capital | $1,127,214,000 | $950,719,000 | $874,261,000 | $523,921,000 |
| Capital Stock | $56,000 | $53,000 | $52,000 | $44,000 |
| Common Stock | $56,000 | $53,000 | $52,000 | $44,000 |
| Non Current Deferred Revenue | $53,098,000 | $75,995,000 | $170,673,000 | $0 |
| Long Term Capital Lease Obligation | $44,339,000 | $46,542,000 | $50,841,000 | $52,170,000 |
| Current Deferred Revenue | $55,967,000 | $59,056,000 | $50,533,000 | $0 |
| Current Capital Lease Obligation | $7,580,000 | $7,538,000 | $46,784,000 | $35,961,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $14,562,000 | $10,438,000 | $5,529,000 | $5,347,000 |
| Current Accrued Expenses | $10,599,000 | $16,507,000 | $4,559,000 | $3,201,000 |
| Dueto Related Parties Current | $5,558,000 | $21,240,000 | $0 | - |
| Investments And Advances | $69,716,000 | $38,277,000 | $27,168,000 | $0 |
| Available For Sale Securities | $69,716,000 | $38,277,000 | $27,168,000 | - |
| Net PPE | $66,467,000 | $70,245,000 | $69,827,000 | $39,890,000 |
| Accumulated Depreciation | $-15,747,000 | $-9,444,000 | $-5,253,000 | $-3,461,000 |
| Gross PPE | $82,214,000 | $79,689,000 | $75,080,000 | $43,351,000 |
| Leases | $38,373,000 | $38,373,000 | $27,153,000 | $2,399,000 |
| Construction In Progress | $0 | $200,000 | $7,792,000 | $1,700,000 |
| Other Properties | $42,628,000 | $40,052,000 | $39,315,000 | $39,011,000 |
| Machinery Furniture Equipment | $1,213,000 | $1,064,000 | $820,000 | $241,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $370,072,000 | $481,696,000 | $307,434,000 | $190,656,000 |
| Preferred Stock | - | - | - | $0 |
Fetched: 2026-04-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-212,585,000 | $-96,901,000 | $186,145,000 | $-101,580,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-210,258,000 | $-83,467,000 | $207,573,000 | $-99,303,000 |
| Cash Flow From Continuing Operating Activities | $-210,258,000 | $-83,467,000 | $207,573,000 | $-99,303,000 |
| Operating Gains Losses | $82,000 | $-260,000 | $174,000 | $3,000 |
| Investing Activities | ||||
| Capital Expenditure | $-2,327,000 | $-13,434,000 | $-21,428,000 | $-2,277,000 |
| Investing Cash Flow | $86,297,000 | $-183,045,000 | $-154,512,000 | $-117,674,000 |
| Cash Flow From Continuing Investing Activities | $86,297,000 | $-183,045,000 | $-154,512,000 | $-117,674,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $131,562,000 | $0 | $299,706,000 | $259,833,000 |
| Financing Cash Flow | $98,534,000 | $-24,087,000 | $279,163,000 | $252,625,000 |
| Cash Flow From Continuing Financing Activities | $98,534,000 | $-24,087,000 | $279,163,000 | $252,625,000 |
| Net Other Financing Charges | $-38,422,000 | - | - | - |
| Net Common Stock Issuance | $131,562,000 | $0 | $299,706,000 | $259,833,000 |
| Common Stock Issuance | $131,562,000 | $0 | $299,706,000 | $259,833,000 |
| Repurchase Of Capital Stock | - | - | $0 | $0 |
| Net Preferred Stock Issuance | - | - | $0 | $0 |
| Preferred Stock Issuance | - | - | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-230,000 | $-39,846,000 | $-29,392,000 | $-9,675,000 |
| Income Tax Paid Supplemental Data | $1,319,000 | $1,635,000 | $212,000 | $0 |
| End Cash Position | $82,878,000 | $108,305,000 | $398,904,000 | $66,680,000 |
| Beginning Cash Position | $108,305,000 | $398,904,000 | $66,680,000 | $31,032,000 |
| Changes In Cash | $-25,427,000 | $-290,599,000 | $332,224,000 | $35,648,000 |
| Proceeds From Stock Option Exercised | $5,624,000 | $15,759,000 | $8,849,000 | $2,467,000 |
| Net Issuance Payments Of Debt | $-230,000 | $-39,846,000 | $-29,392,000 | $-9,675,000 |
| Net Long Term Debt Issuance | $-230,000 | $-39,846,000 | $-29,392,000 | $-9,675,000 |
| Long Term Debt Payments | $-230,000 | $-39,846,000 | $-29,392,000 | $-9,675,000 |
| Net Investment Purchase And Sale | $88,624,000 | $-169,611,000 | $-133,084,000 | $-115,397,000 |
| Sale Of Investment | $495,600,000 | $427,700,000 | $309,345,000 | $158,340,000 |
| Purchase Of Investment | $-406,976,000 | $-597,311,000 | $-442,429,000 | $-273,737,000 |
| Net PPE Purchase And Sale | $-2,327,000 | $-13,434,000 | $-21,428,000 | $-2,277,000 |
| Purchase Of PPE | $-2,327,000 | $-13,434,000 | $-21,428,000 | $-2,277,000 |
| Change In Working Capital | $-57,494,000 | $-30,778,000 | $225,427,000 | $4,452,000 |
| Change In Other Working Capital | $-25,986,000 | $-86,154,000 | $221,206,000 | - |
| Change In Other Current Liabilities | $-10,524,000 | $4,826,000 | $13,461,000 | $3,123,000 |
| Change In Payables And Accrued Expense | $-18,773,000 | $41,939,000 | $-881,000 | $7,024,000 |
| Change In Accrued Expense | $-21,437,000 | $42,009,000 | $5,593,000 | $-395,000 |
| Change In Payable | $2,664,000 | $-70,000 | $-6,474,000 | $7,419,000 |
| Change In Account Payable | $2,664,000 | $-70,000 | $-6,474,000 | $7,419,000 |
| Change In Prepaid Assets | $-2,211,000 | $8,611,000 | $-8,359,000 | $-5,695,000 |
| Other Non Cash Items | $-38,000 | $4,104,000 | $19,881,000 | $64,181,000 |
| Stock Based Compensation | $77,891,000 | $61,086,000 | $41,789,000 | $21,544,000 |
| Amortization Of Securities | $-8,443,000 | $-15,459,000 | $-11,048,000 | $-2,125,000 |
| Depreciation Amortization Depletion | $6,678,000 | $5,188,000 | $2,040,000 | $1,321,000 |
| Depreciation And Amortization | $6,678,000 | $5,188,000 | $2,040,000 | $1,321,000 |
| Gain Loss On Sale Of PPE | $82,000 | $-260,000 | $174,000 | $3,000 |
| Net Income From Continuing Operations | $-228,934,000 | $-107,348,000 | $-70,690,000 | $-188,679,000 |
| Common Stock Payments | - | - | $0 | $0 |
Fetched: 2026-04-19